Abstract: This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

Abstract: This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

Abstract: The present invention relates to (R)-carbidopa and pharmaceutical compositions thereof, and to a combined preparation of (R)-carbidopa and a steroid, and to the use of the same in the treatment or prevention of medical conditions such as pain, inflammatory diseases, immune or autoimmune disorders and tumour growth.

Abstract: (3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z1, Z2, and Z3, Q, R2, A, and R1 are as defined in the claims.

Abstract: The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced) or cardiovascular diseases including myocardial infarction, coronary revascularization or angina. The compounds of the invention form a novel group of related prodrugs of formula (II), where Ar is a 3-chloro-4-fluorophenyl ring, a 3-chlorophenyl ring or a 4-fluorophenyl ring; and R is a hydrolysable group comprising an amino group or an acidic group.

Abstract: A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced), pain, neurodegenerative disease or cardiovascular disease including myocardial infarction, coronary revascularization or angina.

Abstract: The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.

Abstract: The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1/SSAO activity, and their use for the treatment of muscular dystrophy.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z1, Z2, and Z3, Q, R2, A, and R1 are as defined in the claims.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: The compound is used in pharmaceutical compositions and in a method of treatment of a disease or medical condition which benefits from inhibition of gap junction activity by administering to a subject suffering from such disease or condition.

Abstract: Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X=OH, R2=NH2, R5=CH2OH, R6=H, R1 is C5-C6 alkoxy, OCH2Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH2CH2OH, or OCH2CHF2, (5-indanyl)oxy, C1, C2, C5, or C6 alkylamino, (R) or (S)-sec-Butylamino, C5 or C6 cycloalkylamino, exo-norbornane amino, (N-methyl, N-isoamylamino), phenylamino, phenylamino with either methoxy or fluoro substituents, a C2 sulfone group, a C2 alkyl group, a cyano group, a CONH2 group, or 3,5-dimethylphenyl; or when X=H, R2=NH2, R5=CH2OH, R6=H, R1 is n-hexyloxy; or (II) when X=OH, R1=H, R5=CH2OH, R6=H, R2 is NMe2, N-(2-isopentenyl), piperazinyl, (N-Me, N-benzyl), (N-Me, N—CH2Ph(3-Br)), (N-Me, N—CH2Ph(3-CF3)), or (N-Me, N-(2-methoxyethyl)), or OCH2Cyclopentyl; or (III) when X=OH, R5=CONHR3, R6=H: R1 is H, R3 is an isopropyl group, and R2 is either NH2 or a methylamino group (NHMe) or an isoamyl group (CH2CH2CHMe2);